Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Incyte Corp.

www.incyte.com

Latest From Incyte Corp.

Incyte Will File Jakafi For Acute GVHD In US Based On Phase II Success

The JAK1/2 inhibitor may add an indication for acute graft-versus-host disease, though based on a single, open-label Phase II trial that showed a 55% response rate in a high-mortality indication.

Research & Development Clinical Trials

iTeos Says Adios To IDO And Eyes US IPO

An oversubscribed financing round led by new US investor MPM Capital has brought in $75m for the Belgian company. Much of it will be used to advance its potential best-in-class adenosine A2A receptor now that its IDO1 drug has been shelved.

Financing ImmunoOncology

TMB Biomarker Is A Winding Path Rather Than Straight Road

The tumor mutational burden biomarker had a much higher profile at this year's ASCO meeting, promising to help target treatment to individuals, though practical barriers remain and testing still is not ready for prime time yet.

ASCO ImmunoOncology

Pipeline Watch: Phase III Progress With Nimotuzumab, Solriamfetol, And Upadacitinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Approvals Research & Development
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Immune Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Incyte Pharmaceuticals Inc.
  • Incyte Genomics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Incyte Corp.
  • Senior Management
  • Hervé A Hoppenot, MD, Pres. & CEO
    David W Gryska, EVP, CFO
    Reid M Huber, PhD, EVP, CSO
    Vijay Iyengar, MD, EVP, Global Strategy & Corp. Dev.
    Steven H Stein, MD, EVP, CMO
  • Contact Info
  • Incyte Corp.
    Phone: (302) 498-6700
    1801 Augustine Cut-Off
    Wilmington, DE 19803
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register